Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province, China.
J Transl Med. 2024 Jan 5;22(1):24. doi: 10.1186/s12967-023-04815-y.
Upper tract urothelial carcinoma (UTUC) is a rare disease, belonging to the same category of urothelial cancers as bladder cancer (BC). Despite sharing similar non-surgical treatment modalities, UTUC demonstrates a higher metastasis propensity than BC. Furthermore, although both cancers exhibit similar molecular disease emergence mechanisms, sequencing data reveals some differences. Our study investigates the transcriptomic distinctions between UTUC and BC, explores the causes behind UTUC's heightened metastatic tendency, constructs a model for UTUC metastasis and prognosis, and propose personalized treatment strategies for UTUC.
In our research, we utilized differential gene expression analysis, interaction networks, and Cox regression to explore the enhanced metastatic propensity of UTUC. We formulated and validated a prognostic risk model using diverse techniques, including cell co-culture, reverse transcription quantitative polymerase chain reaction (rt-qPCR), western blotting, and transwell experiments. Our methodological approach also involved survival analysis, risk model construction, and drug screening leveraging the databases of CTRPv2, PRISM and CMap. We used the Masson staining technique for histological assessments. All statistical evaluations were conducted using R software and GraphPad Prism 9, reinforcing the rigorous and comprehensive nature of our research approach.
Screening through inflammatory fibrosis revealed a reduction of extracellular matrix and cell adhesion molecules regulated by proteoglycans in UTUC compared with BC, making UTUC more metastasis-prone. We demonstrated that SDC1, LUM, VEGFA, WNT7B, and TIMP3, are critical in promoting UTUC metastasis. A risk model based on these five molecules can effectively predict the risk of UTUC metastasis and disease-free survival time. Given UTUC's unique molecular mechanisms distinct from BC, we discovered that UTUC patients could better mitigate the issue of poor prognosis associated with UTUC's easy metastasis through tyrosine kinase inhibitors (TKIs) alongside the conventional gemcitabine and cisplatin chemotherapy regimen.
The poor prognosis of UTUC because of its high metastatic propensity is intimately tied to inflammatory fibrosis induced by the accumulation of reactive oxygen species. The biological model constructed using the five molecules SDC1, LUM, VEGFA, WNT7B, and TIMP3 can effectively predict patient prognosis. UTUC patients require specialized treatments in addition to conventional regimens, with TKIs exhibiting significant potential.
上尿路尿路上皮癌(UTUC)是一种罕见的疾病,属于与膀胱癌(BC)相同类别的尿路上皮癌。尽管非手术治疗方式相似,但 UTUC 的转移倾向高于 BC。此外,尽管两种癌症具有相似的分子疾病发生机制,但测序数据显示存在一些差异。我们的研究旨在探讨 UTUC 和 BC 之间的转录组差异,探讨 UTUC 转移倾向增强的原因,构建 UTUC 转移和预后模型,并为 UTUC 提出个性化治疗策略。
在我们的研究中,我们利用差异基因表达分析、相互作用网络和 Cox 回归来探讨 UTUC 增强的转移倾向。我们使用多种技术(包括细胞共培养、逆转录定量聚合酶链反应(rt-qPCR)、Western blot 和 Transwell 实验)构建和验证了预后风险模型。我们还使用 CTRPv2、PRISM 和 CMap 数据库进行生存分析、风险模型构建和药物筛选。我们使用 Masson 染色技术进行组织学评估。所有统计评估均使用 R 软件和 GraphPad Prism 9 进行,这加强了我们研究方法的严谨性和全面性。
通过炎症纤维化筛选发现,与 BC 相比,UTUC 中调节蛋白聚糖的细胞外基质和细胞黏附分子减少,使 UTUC 更易转移。我们证明 SDC1、LUM、VEGFA、WNT7B 和 TIMP3 是促进 UTUC 转移的关键因素。基于这五个分子的风险模型可以有效地预测 UTUC 转移的风险和无病生存时间。鉴于 UTUC 的分子机制与 BC 不同,我们发现 UTUC 患者通过酪氨酸激酶抑制剂(TKI)联合常规吉西他滨和顺铂化疗方案,可以更好地减轻 UTUC 易转移导致的预后不良问题。
由于 UTUC 转移倾向高,导致预后不良,这与活性氧积累引起的炎症纤维化密切相关。使用 SDC1、LUM、VEGFA、WNT7B 和 TIMP3 这五个分子构建的生物模型可以有效地预测患者的预后。UTUC 患者除了常规方案外,还需要专门的治疗,TKI 具有显著的潜力。